Priority areas for cannabis and cannabinoid product research in South Africa
Date
2018-06
Journal Title
Journal ISSN
Volume Title
Publisher
AOSIS
Abstract
The legalisation of cannabis for medicinal use is a contentious space both politically and in the
medical community. In 2014, the Medical Innovation Bill introduced by Mario Oriani-Ambrosini
MP, aimed to shift the political and legal positions of cannabis as an illegal substance to one
available for research and medical use. To date, progress on this has been slow. Cannabis and
cannabinoid products are currently available for medicinal use in several countries, including the
Netherlands and 29 states in the United States. Locally, anecdotal reports suggest that many of
our patients with chronic medical conditions are using cannabis and cannabis-derived or
cannabinoid products for symptom alleviation.
Description
CITATION: Augustine, T.N. et al. 2018. Priority areas for cannabis and cannabinoid product research in South Africa. African Journal of Primary Health Care & Family Medicine, 10(1):1-3, doi:10.4102/phcfm.v10i1.1711.
The original publication is available at https://phcfm.org/index.php/phcfm
The original publication is available at https://phcfm.org/index.php/phcfm
Keywords
Cannabis, Medicinal cannabis, HIV, Sensory neuropath, Chronic pain, Cannabis policy
Citation
Augustine, T.N. et al. 2018. Priority areas for cannabis and cannabinoid product research in South Africa. African Journal of Primary Health Care & Family Medicine, 10(1):1-3, doi:10.4102/phcfm.v10i1.1711.